Anticipated timeline and budget
- Application deadline:
- 11 January 2027
- Estimated Project end date:
- 31 March 2028, to be confirmed in the funding agreement
- Grant funding available:
- $200,000 in 2026–2027
$200,000 in 2027–2028 (subject to confirmation of funding availability)
Background
Mild traumatic brain injury (mTBI) is a recognized health concern for Canadian Armed Forces (CAF) members, Veterans, and civilian patients. Blood-based neurological biomarkers released after injury to neurons and astroglia offer a window into the biology of mTBI, but important questions remain about where these signals originate, how they change in the hours and days after injury, what influences their measurement, and how they relate to clinical findings and recovery.
Head computed tomography (CT) identifies acute structural intracranial injury, but a normal CT does not exclude concussion or predict recovery. Better biological understanding could, in time, help clinicians decide when imaging is needed and identify patients who may benefit from closer follow-up. These questions carry particular weight in military operational and remote settings, where imaging and laboratory services may be limited and measurements that can be made rapidly and close to the patient could have value. Findings from acute injury cohorts would nonetheless require further study before being applied to repeated low-level blast exposure, austere environments, or medical evacuation decisions.
Research objectives
The Department of National Defence (DND) invites foundational biomedical research on circulating neurological biomarkers after suspected mTBI. The aim is to clarify what these biomarkers reflect, how measurement conditions influence them, and how they relate to intracranial injury, clinical presentation, and recovery. Applicants may address one or more of the following questions, with emphasis and methods justified by their scientific rationale:
- Biological origins and kinetics. What cellular and physiological processes (neuronal, astroglial, neurovascular, or inflammatory) give rise to circulating biomarkers after suspected mTBI, and how do their concentrations change from the first hours to the days after injury?
- Measurement and interpretation. How do sample type (for example, whole blood, plasma, or serum), time from injury to sampling, sample handling, and analytical method influence measured concentrations, and how do rapid whole-blood measurements relate to established laboratory methods?
- Clinical and imaging correlates. How do biomarker profiles relate to clinical presentation, CT-detected intracranial lesions, advanced neuroimaging, symptoms, and recovery, and what mechanisms might explain discordant findings, such as elevated biomarkers with a normal CT?
- Sources of variation. How do age, sex, extracranial injury, prior brain injury, and occupational or blast exposure history influence biomarker levels and their interpretation?
- Implications for assessment. What do the findings imply for the future use of biomarkers to inform head CT decisions safely, and what further evidence would be needed before application in military, remote, or Veteran care?
Applicants should select and justify the study design, population or biospecimens, biomarkers, analytical methods, sampling strategy, comparators, and statistical approach. Prospective clinical studies, laboratory investigations, analysis of existing well-characterized samples and data, or a combination may be proposed. Prospective designs that combine early and serial sampling, paired sample types, standard-of-care imaging, and clinical follow-up in the same participants are of interest because they allow biology, measurement, and clinical findings to be examined together. Cohorts may include CAF members, Veterans, or civilians, with a clear rationale for military and Veteran relevance.
Glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase-L1 (UCH-L1) are examples of relevant brain-enriched biomarkers; other scientifically justified markers may be proposed. Applicants should justify the suitability, reliability, and regulatory status for research use of any assay proposed. Where diagnostic performance or CT use is examined, proposals should use appropriate reference standards, account for the expected frequency of intracranial injury in sample-size planning, address bias and uncertainty, and distinguish observed outcomes from modelled estimates.
Complementary proteomic or other biomolecular analyses may explore mechanisms of persistent cognitive or neuropsychological symptoms, such as depression or posttraumatic stress disorder (PTSD), where linked to the primary mTBI question and feasible within the budget; exploratory associations should be distinguished from validated clinical decision tools. The opportunity supports research and is not intended to fund product development or operational test and evaluation of a specific device.
Desired outputs
- A final research report by the project end date, including an executive summary, methods, findings, biological interpretation, limitations, implications for future clinical research and care, and priorities for further investigation.
- Peer-reviewed publication submissions or other accessible research outputs, supported by a knowledge exchange plan for clinicians and military and Veteran health stakeholders.
- Brief quarterly progress updates, and a virtual presentation of findings to the sponsor and stakeholders near completion (this may take place after the project end date).
A deployment-ready operational product or procedure is not an expected output. Documentation and outputs must be submitted in English; additional bilingual or accessible dissemination may be proposed.
Applicant qualifications and requirements
- Eligibility. Eligible organizations include educational institutions, research and non-profit organizations, public health and social services institutions, Indigenous organizations, provincial, territorial, and local governments, and eligible international organizations. Individuals and for-profit organizations are not eligible.
- Team. The research must be led by a principal investigator with a PhD, MD, or equivalent qualification in a relevant field, supported by expertise appropriate to the proposed methods (for example, neurotrauma, biomarker science, clinical epidemiology, or neuroimaging) and demonstrated access to the necessary participants, samples, data, and facilities.
- Ethics and safety. Applications may precede research ethics board (REB) approval; the selected applicant and sponsor will coordinate approvals, which must be in place before funds are released. Research involving CAF members may also require Defence Research and Development Canada (DRDC) human research ethics review and Surgeon General health research approval. Describe consent, privacy, data governance, participant safety, and regulatory permissions for research use of assays. Research-only results must be distinguished from information used to guide care, and must not delay clinically indicated imaging or treatment.
- GBA Plus. Proposals should meaningfully incorporate Gender-based Analysis Plus (GBA Plus) in recruitment, analysis, and interpretation, including sex, gender, age, and other relevant intersecting factors, and acknowledge limits to subgroup inference. Engagement of people with lived experience is encouraged where it would strengthen the research.
- Schedule and budget. Propose a realistic schedule to completion by 31 March 2028, with milestones for approvals and start-up, recruitment and data collection, analysis, and dissemination. Allow at least six weeks for administrative arrangements after selection, and longer where approvals require it; work cannot begin until the funding agreement is signed and required REB approvals are in place. Justify costs by category and fiscal year, including publication costs. Institutional overhead is limited to 10%; Veterans Affairs Canada (VAC) may consider a higher rate in exceptional circumstances. Grant funds are disbursed as a lump sum in accordance with the funding agreement, which also sets reporting requirements.
Applications will be screened for program eligibility and relevance, then assessed on scientific merit and potential to advance biological understanding; relevance to CAF members, Veterans, and clinical care; methodological rigour, participant safety, and feasibility; team expertise and access; GBA Plus; budget; and knowledge exchange. DRDC scientific authorities and Canadian Forces Health Services (CFHS) clinical representatives will contribute to the scientific review and assessment of military relevance.
Collaboration and intellectual property
The sponsor may engage with the funded team to clarify military and Veteran relevance and discuss findings. Collaboration, data access, and authorship will reflect actual contributions and institutional policies. The award recipient will own any foreground intellectual property created through the funded research; the sponsor may request permission to use it for its own purposes, and the funding agreement will stipulate that such permission will not be unreasonably withheld.
Application deadline
Please download and submit the Research Funding Application form.
Enquiries
Questions about this funding opportunity can be sent to the VAC Research office.